Loading
Ifinatamab deruxtecan is a B7-H3 ADC showing some of the best response rates ever seen in relapsed small-cell lung cancer.
Ifinatamab deruxtecan is an anti-B7-H3 IgG1 antibody carrying the topoisomerase I inhibitor DXd at a drug-to-antibody ratio of about 8 through a cleavable GGFG linker; B7-H3 is present on most small-cell lung cancers and the permeable payload kills neighbouring cells too. Daiichi Sankyo and Merck are developing it for extensive-stage SCLC after platinum, where the phase 2 IDeate-Lung01 trial reported an objective response rate around 55 percent at the selected 12 mg/kg every-3-weeks dose, among the best seen in relapsed SCLC. The phase 3 IDeate-Lung02 trial versus topotecan is ongoing, and the FDA granted Breakthrough Therapy designation in 2024. Nausea, anaemia, decreased appetite and neutropenia are common, and interstitial lung disease is monitored. It is also being studied in prostate and oesophageal cancer, and offers a lung cancer with few new options a genuinely new mechanism.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Anti-B7-H3 IgG1 with DXd. Connects to B7-H3.
1.Antibody binds B7-H3 on the tumour cell surface
Source: clinicaltrials.gov/study/NCT05280470. Doses are for orientation; the current label governs.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2023-10-20 | Daiichi Sankyo to Merck & Co. (MSD) Patritumab deruxtecan (HER3), ifinatamab deruxtecan (B7-H3) and raludotatug deruxtecan (CDH6) | Co-development | $4.0bn (plus $1.5bn in continuation payments over 24 months) | up to $22bn | source |
Pivotal phase 3 for the B7-H3 ADC from the Merck and Daiichi Sankyo collaboration. Timing is a registry-based estimate. Source
Compare all products across the US, EU, UK, Japan, China and Australia →
Breakthrough Therapy designation, extensive-stage SCLC after platinum source
| Adverse event |
|---|
| Nausea |
| Anaemia |
| Decreased appetite |
| Neutropenia |
| ILD/pneumonitis |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational (phase 3 IDeate-Lung02) | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Ifinatamab deruxtecan" OR ABSTRACT:"Ifinatamab deruxtecan" OR TITLE:"I-DXd" OR ABSTRACT:"I-DXd" OR TITLE:"DS-7300" OR ABSTRACT:"DS-7300") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ifinatamab deruxtecan, not a curated reading list.
Shares A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01), Tetrapeptide GGFG (maleimide-GGFG-aminomethyl), DXd, Topoisomerase-I inhibitor payloads.
Shares B7-H3 (CD276) expression, Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11, Neuroendocrine and small-cell prostate cancer, Extensive-stage small-cell lung cancer.
Shares IDeate-Lung02, Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11, Small cell lung cancer (KEGG map), Neuroendocrine and small-cell prostate cancer.
Shares Tetrapeptide GGFG (maleimide-GGFG-aminomethyl), DXd, Topoisomerase-I inhibitor payloads, Daiichi Sankyo.
Shares Sequencing DLL3 engager and B7-H3 ADC in relapsed SCLC, Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11, Small cell lung cancer (KEGG map), Neuroendocrine and small-cell prostate cancer.
Shares Sequencing DLL3 engager and B7-H3 ADC in relapsed SCLC, Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11, Neuroendocrine and small-cell prostate cancer, Lineage plasticity & neuroendocrine transformation.
Shares A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001), Merck & Co. (MSD), Small-cell lung cancer.
Shares A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02), Metastatic castration-resistant prostate cancer, Merck & Co. (MSD), Prostate cancer.